Eckhard Alt, M.D., Ph.D.
Chairman of the Board
Eckhard U. Alt, M.D., Ph.D., is Professor of Medicine and Biomedical Engineering at Tulane University in New Orleans and was Professor of Medicine at University of Texas MD Anderson Cancer Center in Houston and Technische Universität in Munich. He received his medical degree as Valedictorian from Heidelberg Medical School. After two years in cardiac surgery at the Ludwig Maximillian University in Munich he completed his education at Rechts der Isar Medical Center of the Technische Universität Munich in Internal Medicine/Cardiology.
He is a frequent reviewer and serves on the Editorial Boards of respected journals. From 2001 to 2007, he was President of the International Cardiac and Electrophysiology Society. Prof. Alt has organized major national and international congresses, authored more than 500 publications in peer reviewed journals, books or book chapters. His innovative spirit is demonstrated by more than 600 granted world-wide patents, primarily in the fields of Stem Cells, Electrophysiology, and Interventional Cardiology. He has introduced new therapies to clinical practice, including novel methods and devices such as Rate-adaptive Pacing, Defibrillators, Treatment of Atrial Fibrillation and Stem Cell Treatment. His contributions have substantially influenced the modern practice of medicine. Prof. Alt was elected among the leading 1000 physicians in Germany, the magazine Focus rated him among the “Best 12 Cardiologists in Germany.” He received the Hahn Research Award from the European Society of Thoracic Surgery and from Erasmus University in Rotterdam the Ethica Award as Best Experimental Researcher. In 2009 he was named Entrepreneur of the Year in Munich and Health Care Hero / Innovator of the Year in Houston, TX. In addition to being Chairman of the Board of InGeneron, Inc., he is also Chairman of the Board of ISAR Klinikum in Munich, Germany.
Bobby I. Griffin, Ph.D.
Bobby I. Griffin, Ph.D., retired from a 25 year career with Medtronic, Inc., where he held various positions, including Executive Vice President from 1985 to 1998 and President of Medtronic’s CRM Business from 1991 to 1998. Since his retirement, Mr. Griffin has been a private investor, managing his own fund of companies as well as serving on the advisory boards of Affinity Capital Management Fund III and IV and Sapient Capital Management Fund, in which he also invests. In addition, Mr. Griffin has served on the Board of Directors of several public companies, including MTS Systems Corporation and Urologix, Inc., and is currently a director of several private companies.
Jerry C. Griffin, M.D.
Jerry C. Griffin, M.D., is president of Griffin & Schwartz, Scientific Services, Inc. a management consulting firm in the healthcare products field. Dr. Griffin has assisted several development stage companies in areas ranging from venture and public financing to FDA and clinical trial strategy. In addition, he is currently a member of the Boards of Directors of private companies. During his academic tenure, he held leadership positions in several national and international cardiology organizations and is the author or co-author of five books, four patents, and over 170 medical and scientific articles.
Klaus L. Keller
Klaus L. Keller is founding chairman, CEO, and majority shareholder of Sueba USA Corporation in Houston, Texas. He is active in the area of acquisition, development, and management of US real estate. In addition, Mr. Keller is also a private investor, syndicator, and manager of US real estate investment funds.
Rich Adcock is Chief Innovation Officer at Sanford Health, one of the largest US health care providers. He is an experienced executive in product management, medical devices, health care delivery, and health plan management. Rich Adcock began his career at Sanford in 2004 and held various positions, including director, vice president and executive vice president for Sanford Clinic and president of Sanford Frontiers. Sanford Health is a collaboration partner of InGeneron as well as an investor in the company’s Series D financing.